Clinical Trial: MRD-directed Therapy for Low-risk and Intermediate-risk AML.
Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional
Official Title: Minimal Residual Disease-directed Therapy for Low-risk and Intermediate-risk Acute Myeloid Leukemia.
Brief Summary: Acute myeloid leukemia(AML) patients with favorable and intermediate cytogenetics at diagnosis are generally excluded from first-line allo-SCT. However, these patients may eventually relapse in some of cases. The purpose of this study is to establish risk stratification based on cytogenetics and minimal-residual-disease(MRD) analysis to determine whether a MRD-directed therapy for low and intermediate AML patients has positive results in terms of overall survival.
Detailed Summary:
Sponsor: Nanfang Hospital of Southern Medical University
Current Primary Outcome: overall survival (OS) [ Time Frame: 3 year ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- leukemia relapse rate [ Time Frame: 3 year ]
- disease-free survival (DFS) [ Time Frame: 3 year ]
- Event Free Survival (EFS) [ Time Frame: 3 year ]
Original Secondary Outcome: Same as current
Information By: Nanfang Hospital of Southern Medical University
Dates:
Date Received: August 14, 2016
Date Started: August 2016
Date Completion: December 2019
Last Updated: August 14, 2016
Last Verified: August 2016
